Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 16

1.

High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial.

Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, Cohen V, Small D, Miller WH Jr.

PLoS One. 2015 Apr 7;10(4):e0120228. doi: 10.1371/journal.pone.0120228. eCollection 2015.

2.

Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.

Jacobs C, Hutton B, Ng T, Shorr R, Clemons M.

Oncologist. 2015 Feb;20(2):210-23. doi: 10.1634/theoncologist.2014-0381. Epub 2015 Jan 19. Review.

3.

Ascorbate as a co-factor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression.

Kuiper C, Vissers MC.

Front Oncol. 2014 Dec 10;4:359. doi: 10.3389/fonc.2014.00359. eCollection 2014. Review.

4.

Epigenetic impacts of ascorbate on human metastatic melanoma cells.

Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Böcker A, Niessner H, Lauer UM, Bitzer M, Garbe C, Busch C.

Front Oncol. 2014 Aug 25;4:227. doi: 10.3389/fonc.2014.00227. eCollection 2014.

5.

Extracellular iron diminishes anticancer effects of vitamin C: an in vitro study.

Mojić M, Bogdanović Pristov J, Maksimović-Ivanić D, Jones DR, Stanić M, Mijatović S, Spasojević I.

Sci Rep. 2014 Aug 5;4:5955. doi: 10.1038/srep05955.

6.

Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis.

Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T.

J Orthomol Med. 2012 Jan 1;27(1):9-12.

7.

Intravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice.

Kennard JA, Harrison FE.

Behav Brain Res. 2014 May 1;264:34-42. doi: 10.1016/j.bbr.2014.01.044. Epub 2014 Feb 5.

8.
9.

Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.

Stephenson CM, Levin RD, Spector T, Lis CG.

Cancer Chemother Pharmacol. 2013 Jul;72(1):139-46. doi: 10.1007/s00280-013-2179-9. Epub 2013 May 14.

10.

Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics.

Parrow NL, Leshin JA, Levine M.

Antioxid Redox Signal. 2013 Dec 10;19(17):2141-56. doi: 10.1089/ars.2013.5372. Epub 2013 Jun 19. Review.

11.

Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.

Volta V, Ranzato E, Martinotti S, Gallo S, Russo MV, Mutti L, Biffo S, Burlando B.

PLoS One. 2013;8(3):e58051. doi: 10.1371/journal.pone.0058051. Epub 2013 Mar 6.

12.

Effect of high-dose intravenous vitamin C on inflammation in cancer patients.

Mikirova N, Casciari J, Rogers A, Taylor P.

J Transl Med. 2012 Sep 11;10:189. doi: 10.1186/1479-5876-10-189.

13.

Ascorbic acid: chemistry, biology and the treatment of cancer.

Du J, Cullen JJ, Buettner GR.

Biochim Biophys Acta. 2012 Dec;1826(2):443-57. doi: 10.1016/j.bbcan.2012.06.003. Epub 2012 Jun 20. Review.

14.

Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress.

Klingelhoeffer C, Kämmerer U, Koospal M, Mühling B, Schneider M, Kapp M, Kübler A, Germer CT, Otto C.

BMC Complement Altern Med. 2012 May 2;12:61. doi: 10.1186/1472-6882-12-61.

15.

Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo.

Mikirova NA, Casciari JJ, Riordan NH.

J Angiogenes Res. 2010 Jan 18;2:2. doi: 10.1186/2040-2384-2-2.

16.

Vitamin C and cancer revisited.

Frei B, Lawson S.

Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11037-8. doi: 10.1073/pnas.0806433105. Epub 2008 Aug 5. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk